Fate Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

Martin Hosking

Bahram Valamehr

Tom Tong Lee

Daniel D Shoemaker

Susumu Yamamoto

Eigen Peralta

Chia-Wei Chang

Philippe A Parone

Lisa Guerrettaz

Tatsuo Maeda

Robert S Tacke

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Cells having solid tumor targeting backbone and use thereof

Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.

Chimeric antigen receptor for tumor targeting

Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

Composition and methods for inducing myeloid suppressive cells and use thereof

Growing community of inventors

San Diego, CA, United States of America

Martin Hosking